Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation.
carcinomatous lymphangiosis
cytoreductive nephrectomy
immune checkpoint inhibitor
metastatic renal cell carcinoma
robot‐assisted partial nephrectomy
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
27
09
2021
accepted:
06
02
2022
entrez:
5
5
2022
pubmed:
6
5
2022
medline:
6
5
2022
Statut:
epublish
Résumé
Cytoreductive nephrectomy has been used in combination with systemic therapy for the treatment of metastatic renal cell carcinoma, although its efficacy in the era of immune checkpoint inhibitors remains controversial. A 57-year-old woman was diagnosed with left renal cell carcinoma and lung carcinomatous lymphangiosis (cT3aN0M1). After receiving combined immunotherapy, she achieved complete response for the lung metastases and partial response for the primary tumor. After five months of systemic therapy, she underwent partial nephrectomy to remove the primary tumor, followed by eight courses of nivolumab monotherapy. One year postoperatively, she remained recurrence-free. Cytoreductive partial nephrectomy for surgical consolidation may be a treatment option for metastatic renal cell carcinoma.
Identifiants
pubmed: 35509785
doi: 10.1002/iju5.12427
pii: IJU512427
pmc: PMC9057747
doi:
Types de publication
Case Reports
Langues
eng
Pagination
168-171Informations de copyright
© 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Eur Urol. 2014 Oct;66(4):704-10
pubmed: 24931622
J Urol. 2004 Mar;171(3):1071-6
pubmed: 14767273
N Engl J Med. 2018 Aug 02;379(5):417-427
pubmed: 29860937
Eur Urol. 2020 Jun;77(6):761-763
pubmed: 31911011
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
J Urol. 2006 Nov;176(5):1990-5; discussion 1995
pubmed: 17070231
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
IJU Case Rep. 2022 Mar 25;5(3):168-171
pubmed: 35509785
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
J Immunother Cancer. 2019 Mar 11;7(1):66
pubmed: 30857555
Int J Urol. 2019 Sep;26(9):885-889
pubmed: 31257682
Urol Oncol. 2013 Jan;31(1):36-41
pubmed: 21396834
Cancer. 2020 Sep 15;126(18):4156-4167
pubmed: 32673417
JAMA Oncol. 2019 Feb 1;5(2):164-170
pubmed: 30543350
Urol Oncol. 2019 Dec;37(12):924-931
pubmed: 31522865
Urol Oncol. 2020 Jun;38(6):604.e9-604.e17
pubmed: 32253116
Lancet. 2001 Sep 22;358(9286):966-70
pubmed: 11583750
Urol Oncol. 2018 Feb;36(2):78.e21-78.e28
pubmed: 29128421
Respirol Case Rep. 2017 Jun 08;5(5):e00247
pubmed: 30631445